Perosphere and Daiichi Sankyo enter into a clinical trial agreement
26 April 2013 | By Daiichi Sankyo
Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study...
List view / Grid view
26 April 2013 | By Daiichi Sankyo
Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study...
21 February 2013 | By Boehringer Ingelheim
Findings from two trials...
10 December 2012 | By Boehringer Ingelheim
Results from a new post-hoc analysis...
8 December 2012 | By Bristol-Myers Squibb Company
Results of the Phase 3 AMPLIFY-EXT trial...
8 November 2012 | By Boehringer Ingelheim
Pivotal data from the RELY-ABLE® study have provided additional data...
5 November 2012 | By Boehringer Ingelheim
New findings presented...
31 October 2012 | By Boehringer Ingelheim
Results from RELY-ABLE®...
25 October 2012 | By Daiichi Sankyo
Edoxaban is an investigational, once daily, novel oral factor Xa inhibitor...
29 August 2012 | By Boehringer Ingelheim
New one-year follow-up results from the global RE-LY AF registry...
27 August 2012 | By Boehringer Ingelheim
40,000 people estimated to be saved from a stroke related to non-valvular atrial fibrillation...
24 August 2012 | By Boehringer Ingelheim
Indirect comparison based on the RE-LY® trial and the Rocket AF trial suggests advantages of Pradaxa® in stroke prevention in patients with atrial fibrillation...
9 July 2012 | By European Medicines Agency (EMA)
The EMA has been notified by Sanofi-aventis of its decision to withdraw its marketing authorisation application for Mulsevo...
20 June 2012 | By Boehringer Ingelheim
The design of the RE-ALIGN study published...
18 June 2012 | By Boehringer Ingelheim
Pradaxa® is associated with a substantially shorter interruption of oral anticoagulation therapy...
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...